Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how biomarkers are currently being used in clinical and research contexts, and what it would take for him to use them more often in clinical practice. He also discusses how groundbreaking collaborative research studies, including the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson's Progression Markers Initiative (PPMI), are having major impacts on the field. Chuck is Consultant and Professor of Neurology in the Department of Neurology and The Wayne and Kathryn Preisel Professor of Neuroscience Research at the Mayo Clinic Alix School of Medicine at the Mayo Clinic in Arizona.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Sleep disturbances, such as insomnia, sleep fragmentation, excessive daytime sleepiness, and REM sleep behavior disorder are common in people with Parkinson's disease (PD). Poor sleep quality can also impact other domains of function, including motor function. Prior research has shown that a type of photoreceptor cell in the retina, called melanopsin cells, provide the main light signals to the brain to initiate sleep, and function of these cells is impaired in PD. Dr. Beatix Feigl and her colleagues developed a novel light therapy intervention that selectively activates the melanopsin photoreceptor cells, and in this episode, she discusses the results of a recent randomized controlled trial evaluating the efficacy of this melanopsin photoreceptor-directed light therapy on sleep and circadian rhythm, as well as motor behaviors. She also discusses her earlier work on melanopsin cells that led to the development of standard measures to assess their function. Beatrix is an Ophthalmologist and an Associate Professor in the School of Biomedical Sciences and Center for Vision and Eye Research, as well as the Faculty of Health, at the Queensland University of Technology.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Though existing evidence supports that dysfunction in the clearing of cellular debris plays an important role in the development of Parkinson's disease, many unanswered questions remain regarding the mechanisms of the autophagy-lysosomal pathway involved in this process. In particular, research in the field has been limited by a lack of reliable, quantitative tests for monitoring autophagy-lysosome activity. In this interview, Dr. Zhenyu Yue describes his research investigating the cellular and molecular mechanisms for Parkinson's disease and other neurodegenerative diseases, focusing on their work examining the regulation of the autophagy-lysosomal pathway, potential therapeutic targets, and MJFF-funded research that aims to develop sensitive, robust autophagy-lysosome assays to facilitate the discovery of biomarkers for PD using stem cell-derived neurons and biofluids. Zhenyu is the Aidekman Research Professor in the Department of Neurology and Friedman Brain Institute at the Icahn School of Medicine at Mount Sinai. He is also the Director of the Center of Parkinson’s Disease Neurobiology and Director of Basic Research of Movement Disorders at Mount Sinai.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. Dr. Paul Lingor discusses his work in this area to identify patterns of bioelements in CSF that could serve as PD biomarkers. Beyond CSF, he is also examining tear fluid as a potential biomarker source that is easier to collect. In addition to work on biomarkers, Paul has been involved in developing and evaluating new treatments for Parkinson's disease. In this episode, he discusses an ongoing phase II clinical trial evaluating the ROCK inhibitor Fasudil, as well as research examining combinations of advanced therapies for people with later-stage Parkinson's disease. Paul is Professor of Neurology at the Technical University of Munich and head of the outpatient clinics for motor neuron disease and co-head of the outpatient clinics for Parkinson’s disease.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches. Dr. Antonio Strafella discusses current practices for using molecular imaging biomarkers in research and in the clinic, the process of developing new biomarkers, as well as promising biomarkers that are in development. He also discusses limitations, implementation challenges, and the potential use of AI to enhance diagnostics in the future. Antonio is the Krembil-Rossy Chair in Molecular Imaging of Neurodegenerative Diseases and Professor in the Department of Medicine within the Division of Neurology at the Toronto Western Hospital (University Health Network, University of Toronto). He also serves as Director of Clinical Research and Translation with the Temerty Faculty of Medicine at the University Toronto, and he is a movement disorder neurologist in the Edmond J. Safra Program in Parkinson’s Disease and Morton & Gloria Shulman Movement Disorders Clinic at the Toronto Western Hospital.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Prior studies have established links between poor olfaction and Parkinson's disease, and impaired sense of smell is a common prodromal symptom of Parkinson's disease. The causes and mechanisms of prodromal neurodegeneration are actively being researched. However, environmental exposure to pesticides or other chemicals may trigger or modify the course of neurodegeneration, potentially leading to the development of Parkinson's disease over time. In this episode, Dr. Honglei Chen shares his research on environmental causes of neurodegenerative diseases, focusing particularly on evidence linking olfaction, environmental exposure, and Parkinson’s disease. Better understanding how environmental factors may contribute (alone or in combination with genetic factors) to the pathogenesis of Parkinson's disease may lead to new approaches to prevent or slow the progression of neurodegeneration. Honglei is the MSU Research Foundation Professor of Epidemiology and Biostatistics at Michigan State University.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Gait impairments such as slow speed, small steps, and high variability from step to step are common in people with Parkinson's disease, and these changes begin to occur early in the course of disease. Freezing of gait may develop later for some individuals, and it has been linked to falls and other adverse outcomes. When the quality of walking declines, it can lead to a reduction in the quantity of walking and overall physical activity, which is also related to poorer health outcomes. To prevent this cascade of events, Dr. Gammon Earhart is developing and evaluating interventions to improve gait and increase physical activity in People with Parkinson's disease. In this episode, she discusses how she and collaborators are conducting studies on different approaches, including a mobile health application, self-generated rhythmic cues in the form of singing, and mindfulness training, to improve aspects of walking and physical activity in people with Parkinson's disease. Gammon is Professor of Physical Therapy, Neurology, and Neuroscience, Associate Dean for Physical Therapy, and Director of the Program in Physical Therapy at Washington University School of Medicine in St. Louis.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.

Improving our understanding of the complex neural circuits involved in normal function of the basal ganglia and other parts of the brain impacted by Parkinson's disease is critical for developing more targeted and more effective treatment approaches. In this episode, Dr. Aryn Gittis discusses her research examining how the activity of specific basal ganglia circuits relates to motor control in both health and pre-clinical models of movement disorders like Parkinson's disease. She describes new research on basal ganglia circuits that expands upon existing theoretical frameworks and provides important insights that can be leveraged to improve current therapies for Parkinson's disease by better targeting specific cell types in relevant circuits. Aryn also shares details about her ongoing project evaluating the impacts of stimulus location for a novel pattern of deep brain stimulation (DBS) that has been shown to provide long-lasting therapeutic effects in pre-clinical models. Aryn is Professor of Biological Sciences and the Neuroscience Institute at Carnegie Mellon University.

This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.